Idogen AB Year-end report 1 January-31 December 2019

FOURTH QUARTER (OCTOBER-DECEMBER 2019)

• Other operating income amounted to KSEK 1,225 (3,766)

• Operating loss was KSEK -8,005 (-4,796).

• Loss for the period totalled KSEK -8,207 (-4,806).

• Cash flow from operating activities was KSEK –7,790 (-432)

• Loss per share was SEK -0.17 (-0.19)

• The proposed dividend is SEK 0.00/share (0.00)
   

PERIOD (JANUARY-DECEMBER 2019)

• Other operating income amounted to KSEK 4,192 (3,766)

• Operating loss was KSEK -32,826 (-27,861).

• Loss for the period totalled KSEK -32,694 (-27,634)

• Cash flow from operating activities was KSEK –34,974 (-10,394)

• Loss per share was SEK -0.67 (-1.27)

SIGNIFICANT EVENTS IN THE FOURTH QUARTER

• On 13 November, it was announced that Idogen had entered into a collaboration agreement with the Radboud University Medical Center for cell therapy manufacturing for haemophilia when patients are developing inhibitory antibodies against their life-saving therapy with coagulation factor VIII.

• On 13 December, Idogen announced that the company had filed a patent application for its new tolerogenic cell therapy.
   

SIGNIFICANT EVENTS DURING THE PERIOD

• Anders Karlsson became the company’s new CEO on 20 August.

• At the end of June, Idogen announced that CEO Lars Hedbys had resigned after five years as CEO of the company.

• In June, Idogen announced that the company had successfully developed a new patentable tolerance-inducing method to replace zebularine in development of the company’s tolerogenic cell therapy. The company has therefore written down the value of patents related to zebularine in an amount of MSEK 4.6.

• In April, Idogen announced that NextCell Pharma AB had contacted the company’s Board of Directors regarding a possible merger. In May, Idogen reported that discussions between the companies had been abandoned.

• In January, Idogen announced that it is extending and broadening its preclinical development programme for tolerogenic cell therapy. This means the clinical trials for IDO 8 and IDO T may be delayed by six months and start in the second half of 2020 for IDO 8 and first half of 2021 for IDO T.

 SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

• In January, the company announced a decision regarding a rights issue of gross MSEK 29.

• In January, notice was given of an Extraordinary General Meeting on 17 February in Lund.

• No other significant events occurred after the end of the period that affected the results or financial position.
   

This information is such that Idogen AB is obligated to publish under the EU Market Abuse Regulation (MAR) and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, on 29 January 2020.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT:
Anders Karlsson, Chief Executive Officer
Phone: +46 (0) 709 18 00 10
E-mail: anders.karlsson@idogen.com
 

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com